Hanmi Pharmaceutical (128940) stock
KOSPI · Pharmaceuticals
As of Nov 16, 11:42 AM KST
- Market cap
- KRW 5.9 trillion
- As of Nov 16, 2026
- P/E
- 31.12x
- Trailing twelve months
- P/B
- 4.53x
- Latest reported equity
- P/S
- 3.52x
- Trailing twelve months
- ROE
- 14.6%
- Trailing twelve months
- Dividend yield
- 0.44%
- Dividends observed in the last year
Multiples use the price as of Nov 16, 2026 and may differ from the current price.
- Market cap
- KRW 5.9 trillion
- As of Nov 16, 2026
- P/E
- 31.12x
- Trailing twelve months
- P/B
- 4.53x
- Latest reported equity
- P/S
- 3.52x
- Trailing twelve months
- ROE
- 14.6%
- Trailing twelve months
- Dividend yield
- 0.44%
- Dividends observed in the last year
Multiples use the price as of Nov 16, 2026 and may differ from the current price.
Compares the share price with the company's earnings, net assets and sales. Check trading status and financial notes separately.
Price date for the multiples · Nov 16, 2026 · Financial period · Trailing twelve months
P/E and P/S use the latest four quarters where available · P/B uses the latest equity · Computed in-house by ChickenStock
P/E
31.12x
P/B
4.53x
P/S
3.52x
Earnings and dividend metrics▾
Earnings
EPS
KRW 14,765
Earnings per share
BPS
KRW 101,471
Book value per share
ROE
14.6%
Return on equity
- EPS — what one share earned over the last four quarters. This company earned KRW 14,765 per share.
- BPS — net assets divided by the number of shares. Each share is backed by KRW 101,471 of net assets.
- ROE — how much the company earned on shareholder equity over a year: 14.6%.
Dividends
1 observed in the last year · Record dates: Mar
Yield
0.44%
Dividend per share
KRW 2,000
Payout ratio
14.6%
Consecutive years
4+ yrs
Yield uses dividends observed over the last year (by record date) · Dividend per share and payout ratio are for fiscal 2025.
- Dividend yield — dividends divided by the share price (or market cap). It falls when the price rises.
- Dividend per share — the fiscal-year dividend per share. For one hundred shares that is about KRW 200,000 before tax.
- Payout ratio — 14.6% of earnings was paid out as dividends.
- Consecutive years — dividends were paid every year for more than 4 years. That does not mean they will continue.
Reference only · not a promise of future dividends
ⓘ What are these valuation metrics?▾
P/E = share price ÷ earnings per share (EPS)
P/B = share price ÷ book value per share (BPS)
P/S = share price ÷ sales per share
P/E shows how many times annual earnings per share the price is; not all earnings are paid to shareholders. P/B compares the price with net assets, and P/S with sales.
Higher or lower is not good or bad by itself. Typical levels differ by industry; read P/B alongside ROE and P/S alongside margins.
ChickenStock computes these from DART financial filings: net income attributable to owners of the parent and revenue are summed over the latest four quarters, equity is the latest reported equity, and prices are KRX closing prices.
A negative P/E means a net loss. Reference information only, not a recommendation to buy or sell.
Earnings
Revenue, operating profit and net income from periodic reports filed with DART, Korea’s regulatory filing system.
| Period | Revenue | Operating profit | Net income | Revenue YoY |
|---|---|---|---|---|
| Q2 2026Consolidated · Filed Aug 14, 2026 | KRW 467.2 billion | KRW 131.1 billion | KRW 84.1 billion | +29.3% |
| Q1 2026Consolidated · Filed May 15, 2026 | KRW 392.9 billion | KRW 53.6 billion | KRW 51.1 billion | +0.5% |
| Q4 2025Consolidated · Filed Mar 20, 2026 | KRW 433 billion | KRW 83.3 billion | KRW 54.1 billion | — |
| Q3 2025Consolidated · Filed Nov 14, 2025 | KRW 362.3 billion | KRW 55.1 billion | KRW 45.4 billion | +0.1% |
| Q2 2025Consolidated · Filed Aug 14, 2025 | KRW 361.3 billion | KRW 60.4 billion | KRW 43 billion | -4.5% |
| Q1 2025Consolidated · Filed May 15, 2025 | KRW 390.9 billion | KRW 59 billion | KRW 44.7 billion | -3.2% |
| Period | Revenue | Operating profit | Net income | Revenue YoY |
|---|---|---|---|---|
| FY2025Consolidated · Filed Mar 20, 2026 | KRW 1.5 trillion | KRW 257.8 billion | KRW 187.1 billion | — |
| FY2024Consolidated · Filed Mar 18, 2025 | KRW 1.5 trillion | KRW 216.2 billion | KRW 140.4 billion | — |
- Q2 2026 is computed as H1 2026 minus Q1 2026.
- Q4 2025 is computed as FY2025 minus 9M 2025.
- Q3 2025 is computed as 9M 2025 minus H1 2025.
- Q2 2025 is computed as H1 2025 minus Q1 2025.
Short selling and securities lending
Short sales as a share of trading value, the reported short position and the securities lending balance.
- Short-sale share
- 6.45%
- Of trading value on Nov 13, 2026
- Short-sale value
- KRW 6.16 billion
- Previous 20-day average 9.49%
- Net short position
- 251,281 shares
- As of Nov 11, 2026 · reported with a two-trading-day lag
- Lending balance
- 776,551 shares
- As of Nov 13, 2026 · 6.06% of listed shares
| Date | Share | Value |
|---|---|---|
| Nov 13, 2026 | 6.45% | KRW 6.16 billion |
| Nov 12, 2026 | 6.85% | KRW 12.01 billion |
| Nov 11, 2026 | 5.93% | KRW 7.11 billion |
| Nov 10, 2026 | 10.05% | KRW 8.28 billion |
| Nov 9, 2026 | 11.47% | KRW 10.21 billion |
| Nov 6, 2026 | 13.60% | KRW 27.76 billion |
| Nov 5, 2026 | 10.69% | KRW 18.67 billion |
| Nov 4, 2026 | 9.04% | KRW 4.99 billion |
| Nov 3, 2026 | 13.16% | KRW 6.53 billion |
| Nov 2, 2026 | 13.43% | KRW 10.12 billion |
The short-sale share is short-sale value divided by total trading value that day. The lending balance also includes stock lent for purposes other than short selling.
Filings
Major filings received by DART, Korea’s regulatory filing system.
- Technology or Regulatory Approval(Korean)Oct 30, 2026
- Decision on Share CancellationOct 27, 2026 · Share CancellationEnglish
- Preliminary Consolidated Operating Results (Fair Disclosure)Oct 27, 2026 · Preliminary EarningsEnglish
- Technology or Regulatory Approval(Korean)Oct 7, 2026
- Report on Specified Securities Held by Executives and Major ShareholdersOct 6, 2026 · Insider Ownership ReportEnglish
- Report on Major Holdings of Shares (Short Form)Oct 2, 2026 · Major Holding ReportEnglish
- Material Management Information for Investment Decisions(Korean)Sep 29, 2026 · Material Management Information
- Report on Major Holdings of Shares (General Form)Sep 29, 2026 · Major Holding ReportEnglish
Filings with a published English version open in English; the rest link to the Korean original.
Hanmi Pharmaceutical (128940) stock information
KOSPI
Hanmi Pharmaceutical (128940) is listed on KOSPI. Its market capitalization is about KRW 5.9 trillion. On trailing-twelve-month earnings the P/E ratio is 31.12, and the P/B ratio is 4.53. Return on equity is 14.6%. These figures are computed in-house from official filings and are reference information only.
Hanmi Pharmaceutical — frequently asked questions
- What is the P/E ratio of Hanmi Pharmaceutical (128940)?
- On a trailing-twelve-month basis, 128940 trades at a P/E ratio of 31.12. It is calculated as market capitalization divided by net income attributable to controlling interests, using official filings. Reference information only.
- What is the market capitalization of Hanmi Pharmaceutical?
- 128940 has a market capitalization of about KRW 5.9 trillion. The figure moves with the share price and is refreshed each trading day.
- Does Hanmi Pharmaceutical pay a dividend?
- 128940 has a dividend yield of about 0.44%, based on disclosed payment history. Dividend policy can change; this is reference information only.
- Is this page investment advice?
- No. Every figure on this page is factual reference information compiled from public filings. It is not investment advice, not a price forecast and not a recommendation to buy or sell. Investment decisions rest with the user.
All metrics, scores, and content provided by ChickenStock are reference information derived from market data. They are not investment advice or a solicitation to trade. Investment decisions and their consequences rest with the user.